Pharming Group N.V.
ENXTAM:PHARM Stock Report
Pharming Group Past Earnings Performance Pharming Group's earnings have been declining at an average annual rate of -56.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-56.7%
Earnings growth rate
Biotechs Industry Growth 14.8% Revenue growth rate 6.5% Return on equity -7.9% Net Margin -6.2% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023) Oct 25
Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023) Aug 02
First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023) May 08
Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022) Mar 14 Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19
Show all updates
Consensus estimates of losses per share improve by 14% Nov 01
Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023) Oct 25
Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation Oct 10
New minor risk - Share price stability Sep 28
Price target decreased by 7.8% to €1.78 Aug 26
New minor risk - Share price stability Aug 07
Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023) Aug 02
Insufficient new directors Jun 02
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union Jun 02
Pharming Group N.V. Provides Revenue Guidance for 2024 May 09
First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023) May 08 Pharming Group N.V. announced that it expects to receive €100 million in funding Apr 20
Price target increased by 11% to €2.00 Mar 18
Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022) Mar 14 Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price Feb 14
Consensus estimates of losses per share improve by 31% Jan 12
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt? Nov 11
Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded Nov 08
Consensus estimates of losses per share improve by 34% Nov 02
New minor risk - Shareholder dilution Oct 30
Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022) Oct 27
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director Sep 26
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate Aug 23
Consensus EPS estimates fall by 140% Aug 13
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan Aug 09
First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022) Aug 03
Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer Aug 03
Now 20% undervalued Jul 24
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt? Jun 20
Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor May 18
Investor sentiment improves as stock rises 15% May 10
Price target increased by 8.9% to €1.83 Mar 27
Investor sentiment improves as stock rises 18% Mar 27
Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021) Mar 17
Is Pharming Group (AMS:PHARM) Using Too Much Debt? Mar 16
Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe Feb 18
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price Feb 17
Now 20% undervalued Feb 08
Now 20% undervalued Jan 20
Investor sentiment improved over the past week Jan 16
Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition Dec 15 Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023
Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease Dec 08
High number of new directors Nov 16
Investor sentiment improved over the past week Nov 03
Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib Oct 29
Third quarter 2022 earnings: EPS exceeds analyst expectations Oct 27
Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib Oct 11
Price target increased to €13.52 Sep 29
Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Sep 28
Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021) Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt? Aug 05
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Aug 02
Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS Aug 01
Consensus forecasts updated May 19
First quarter 2022 earnings: EPS misses analyst expectations May 13
GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM). May 13
High number of new directors Apr 27
Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA Apr 26 GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million. Apr 23
Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting Apr 03
Consensus revenue estimates fall by 14% Mar 24
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next Mar 21
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat Mar 19
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 18
Price target decreased to €1.80 Mar 09
Is Pharming Group (AMS:PHARM) Using Too Much Debt? Feb 20
Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome Feb 02
Now 21% undervalued after recent price drop Jan 13
Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe Jan 06
Consensus forecasts updated Dec 26
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price Oct 29
Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST® Sep 15
Price target increased to €10.75 Aug 17
Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020) Aug 10
Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome Jun 24
Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly Jun 03
Independent Non-Executive Director has left the company May 28
Independent Non-Executive Director has left the company May 28
Consensus EPS estimates fall to €0.05 May 20
First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020) May 14
Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM) May 12
Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019) Apr 11
Executive Director & CEO recently bought €489k worth of stock Mar 30
Revenue & Expenses Breakdown
How Pharming Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History ENXTAM:PHARM Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 286 -18 195 72 30 Jun 24 278 -13 187 72 31 Mar 24 258 -11 184 72 31 Dec 23 245 -11 175 69 30 Sep 23 219 -22 160 68 30 Jun 23 206 -16 157 60 31 Mar 23 202 -2 140 53 31 Dec 22 206 14 127 53 30 Sep 22 204 30 110 69 30 Jun 22 202 21 100 70 31 Mar 22 202 11 94 70 31 Dec 21 199 16 91 65 30 Sep 21 200 22 88 48 30 Jun 21 200 31 83 44 31 Mar 21 202 37 79 41 31 Dec 20 212 38 76 39 30 Sep 20 212 44 75 33 30 Jun 20 202 46 70 32 31 Mar 20 202 42 69 33 01 Jan 20 189 41 66 33 30 Sep 19 175 38 58 38 30 Jun 19 175 34 60 36 31 Mar 19 158 29 55 32 31 Dec 18 155 29 54 33 30 Sep 18 152 -29 56 27 30 Jun 18 138 -44 53 25 31 Mar 18 128 -80 53 24 31 Dec 17 108 -91 45 22 30 Sep 17 76 -53 32 21 30 Jun 17 47 -47 21 20 31 Mar 17 31 -21 13 17 31 Dec 16 17 -18 8 16 30 Sep 16 12 -16 6 17 30 Jun 16 12 -15 6 16 31 Mar 16 13 -14 6 17 31 Dec 15 12 -11 5 15 30 Sep 15 29 8 6 14 30 Jun 15 27 9 5 14 31 Mar 15 23 10 4 13 31 Dec 14 26 -7 4 14 30 Sep 14 6 -29 3 15 30 Jun 14 6 -35 3 14 31 Mar 14 11 -35 3 15 31 Dec 13 9 -21 3 14
Quality Earnings: PHARM is currently unprofitable.
Growing Profit Margin: PHARM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHARM is unprofitable, and losses have increased over the past 5 years at a rate of 56.7% per year.
Accelerating Growth: Unable to compare PHARM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHARM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: PHARM has a negative Return on Equity (-7.89%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
